Morgan Sturgeon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Morgan Sturgeon has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Garrett R. Rettig
Integrated DNA Technologies, Coralville, USA
5 shared publications - Gavin Kurgan
Integrated DNA Technologies, Coralville, USA
5 shared publications - Rolf Turk
Integrated DNA Technologies, Coralville, USA
5 shared publications - Ashley M. Jacobi
Integrated DNA Technologies, Coralville, USA
4 shared publications - Kyle J. Kinney
Integrated DNA Technologies, Coralville, USA
4 shared publications - Mark A. Behlke
Integrated DNA Technologies, Coralville, USA
4 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10695
Author Correction: UNCOVERseq enables sensitive and controlled gene editing off-target nomination across CRISPR-Cas modalities and systems
- 12 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10695
Open AccessAuthor Correction: UNCOVERseq enables sensitive and controlled gene editing off-target nomination across CRISPR-Cas modalities and systems
- Open Access
- 11 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 6533
UNCOVERseq enables sensitive and controlled gene editing off-target nomination across CRISPR-Cas modalities and systems
The rapid expansion of CRISPR-Cas gene editing enables new therapeutic strategies but complicates assessment of unintended editing risks due to emerging modalities and unclear analytical standards. We present UNCOVERseq (Unbiased Nomination of CRISPR Off-target Variants using Enhanced RhPCR), an improved in cellulo off-target nomination workflow that sensitively identifies rare off-target events using defined inputs and analytical process controls. Using an inter-method off-target confirmation benchmarking dataset, UNCOVERseq demonstrates high analytical sensitivity (97.6%) and precision (78%), outperforming published nomination methods. We apply UNCOVERseq across 192 guide RNAs and identify six guides spanning a broad specificity range, enabling relative risk assessment across S. pyogenes Cas9, high-fidelity variants, and base editors in hematopoietic stem and progenitor cells. We further show that double-strand break nomination sites retain strong rank-order concordance with single-strand break–mediated base editing. Together, these results establish UNCOVERseq as a robust framework for informed off-target risk assessment in translational gene-editing systems.
- 11 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 6533
Open AccessUNCOVERseq enables sensitive and controlled gene editing off-target nomination across CRISPR-Cas modalities and systems
The rapid expansion of CRISPR-Cas gene editing enables new therapeutic strategies but complicates assessment of unintended editing risks due to emerging modalities and unclear analytical standards. We present UNCOVERseq (Unbiased Nomination of CRISPR Off-target Variants using Enhanced RhPCR), an improved in cellulo off-target nomination workflow that sensitively identifies rare off-target events using defined inputs and analytical process controls. Using an inter-method off-target confirmation benchmarking dataset, UNCOVERseq demonstrates high analytical sensitivity (97.6%) and precision (78%), outperforming published nomination methods. We apply UNCOVERseq across 192 guide RNAs and identify six guides spanning a broad specificity range, enabling relative risk assessment across S. pyogenes Cas9, high-fidelity variants, and base editors in hematopoietic stem and progenitor cells. We further show that double-strand break nomination sites retain strong rank-order concordance with single-strand break–mediated base editing. Together, these results establish UNCOVERseq as a robust framework for informed off-target risk assessment in translational gene-editing systems.
- Open Access
Sensitive Chromosomal Translocation Quantitation from Amplicon Sequencing Using Primer-Anchored Statistical Translocation Analysis (PASTA)
Chromosomal translocations are rare structural rearrangement outcomes of genome editing, requiring analytical frameworks that combine high quantitative accuracy with performant sensitivity and specificity. Amplicon sequencing offers a scalable means to detect rare rearrangements with ultra-deep targeted sequencing, but existing methods often rely on heuristic thresholds or ad hoc normalization steps that limit reproducibility and have unknown analytical performance. Here, we present a computational tool we call PASTA (Primer-Anchored Statistical Translocation Analysis), using a count-based differential-event statistical framework to quantify and statistically confirm translocation junctions from targeted amplicon sequencing data. Comparison of this method to ddPCR demonstrates that quantitation is highly accurate, and outperforms other NGS-based methods even when randomized adapter chemistry is not present in amplicon sequencing structures. To measure analytical performance, we create a benchmarking dataset for measuring chromosomal translocation analysis performance with frequencies ranging from 1% to sub-0.01%, and demonstrate that the method can detect frequencies down to 0.01% with >75% sensitivity when sufficient read depth is present. Taken together, this work demonstrates using amplicon sequencing with PASTA as a bioinformatics analysis tool is a solution for translocation detection in amplicon sequencing genotoxicity assessments, enabling identification of rare genome rearrangements in both research and preclinical applications
Open AccessSensitive Chromosomal Translocation Quantitation from Amplicon Sequencing Using Primer-Anchored Statistical Translocation Analysis (PASTA)
Chromosomal translocations are rare structural rearrangement outcomes of genome editing, requiring analytical frameworks that combine high quantitative accuracy with performant sensitivity and specificity. Amplicon sequencing offers a scalable means to detect rare rearrangements with ultra-deep targeted sequencing, but existing methods often rely on heuristic thresholds or ad hoc normalization steps that limit reproducibility and have unknown analytical performance. Here, we present a computational tool we call PASTA (Primer-Anchored Statistical Translocation Analysis), using a count-based differential-event statistical framework to quantify and statistically confirm translocation junctions from targeted amplicon sequencing data. Comparison of this method to ddPCR demonstrates that quantitation is highly accurate, and outperforms other NGS-based methods even when randomized adapter chemistry is not present in amplicon sequencing structures. To measure analytical performance, we create a benchmarking dataset for measuring chromosomal translocation analysis performance with frequencies ranging from 1% to sub-0.01%, and demonstrate that the method can detect frequencies down to 0.01% with >75% sensitivity when sufficient read depth is present. Taken together, this work demonstrates using amplicon sequencing with PASTA as a bioinformatics analysis tool is a solution for translocation detection in amplicon sequencing genotoxicity assessments, enabling identification of rare genome rearrangements in both research and preclinical applications
- Open Access
UNCOVERseq Enables Sensitive and Controlled Gene Editing Off-Target Nomination Across CRISPR-Cas Modalities and Systems
The rapid development of CRISPR-Cas gene editing technologies has revolutionized genetic medicine, offering unprecedented precision and potential for treating a wide array of genetic disorders. However, assessing the risks of unintended gene editing effects remains critical, and is complicated by new editing modalities and unclear analytical guidelines. We present UNCOVERseq (Unbiased Nomination of CRISPR Off-target Variants using Enhanced RhPCR), an improved in cellulo off-target nomination workflow designed to sensitively nominate off-target sites (S.p. Cas9 and derived high-fidelity variants / base editors) in a translational system involving hematopoietic stem and progenitor cells (HSPCs). Additionally, we established that double-strand break (DSB) editing retains a strong, positive rank correlation to single-strand break (SSB)-mediated base editing, highlighting the importance of DSB nomination sites as candidate loci for base editing. Overall, UNCOVERseq improves informed risk assessment of gene editing in translational systems by enhancing the quality of off-target nomination.
Open AccessUNCOVERseq Enables Sensitive and Controlled Gene Editing Off-Target Nomination Across CRISPR-Cas Modalities and Systems
The rapid development of CRISPR-Cas gene editing technologies has revolutionized genetic medicine, offering unprecedented precision and potential for treating a wide array of genetic disorders. However, assessing the risks of unintended gene editing effects remains critical, and is complicated by new editing modalities and unclear analytical guidelines. We present UNCOVERseq (Unbiased Nomination of CRISPR Off-target Variants using Enhanced RhPCR), an improved in cellulo off-target nomination workflow designed to sensitively nominate off-target sites (S.p. Cas9 and derived high-fidelity variants / base editors) in a translational system involving hematopoietic stem and progenitor cells (HSPCs). Additionally, we established that double-strand break (DSB) editing retains a strong, positive rank correlation to single-strand break (SSB)-mediated base editing, highlighting the importance of DSB nomination sites as candidate loci for base editing. Overall, UNCOVERseq improves informed risk assessment of gene editing in translational systems by enhancing the quality of off-target nomination.
- Open Access
- 1 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 478-491
CRISPAltRations: A validated cloud-based approach for interrogation of double-strand break repair mediated by CRISPR genome editing
- 1 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 478-491
Open AccessCRISPAltRations: A validated cloud-based approach for interrogation of double-strand break repair mediated by CRISPR genome editing
- Open Access
- 24 May 2021
- Published by Wiley in Epilepsia Open
- Vol. 6 (3) , 528-538
The opioid antagonist naltrexone decreases seizure‐like activity in genetic and chemically induced epilepsy models
Objective: A significant number of epileptic patients fail to respond to available anticonvulsive medications. To find new anticonvulsive medications, we evaluated FDA‐approved drugs not known to be anticonvulsants. Using zebrafish larvae as an initial model system, we found that the opioid antagonist naltrexone exhibited an anticonvulsant effect. We validated this effect in three other epilepsy models and present naltrexone as a promising anticonvulsive candidate.Methods: Candidate anticonvulsant drugs, determined by our prior transcriptomics analysis of hippocampal tissue, were evaluated in a larval zebrafish model of human Dravet syndrome (scn1Lab mutants), in wild‐type zebrafish larvae treated with the pro‐convulsant drug pentylenetetrazole (PTZ), in wild‐type C57bl/6J acute brain slices exposed to PTZ, and in wild‐type mice treated with PTZ in vivo. Abnormal locomotion was determined behaviorally in zebrafish and mice and by field potential in neocortex layer IV/V and CA1 stratum pyramidale in the hippocampus.Results: The opioid antagonist naltrexone decreased abnormal locomotion in the larval zebrafish model of human Dravet syndrome (scn1Lab mutants) and wild‐type larvae treated with the pro‐convulsant drug PTZ. Naltrexone also decreased seizure‐like events in acute brain slices of wild‐type mice, and the duration and number of seizures in adult mice injected with PTZ.Significance: Our data reveal that naltrexone has anticonvulsive properties and is a candidate drug for seizure treatment.
- 24 May 2021
- Published by Wiley in Epilepsia Open
- Vol. 6 (3) , 528-538
Open AccessThe opioid antagonist naltrexone decreases seizure‐like activity in genetic and chemically induced epilepsy models
Objective: A significant number of epileptic patients fail to respond to available anticonvulsive medications. To find new anticonvulsive medications, we evaluated FDA‐approved drugs not known to be anticonvulsants. Using zebrafish larvae as an initial model system, we found that the opioid antagonist naltrexone exhibited an anticonvulsant effect. We validated this effect in three other epilepsy models and present naltrexone as a promising anticonvulsive candidate.Methods: Candidate anticonvulsant drugs, determined by our prior transcriptomics analysis of hippocampal tissue, were evaluated in a larval zebrafish model of human Dravet syndrome (scn1Lab mutants), in wild‐type zebrafish larvae treated with the pro‐convulsant drug pentylenetetrazole (PTZ), in wild‐type C57bl/6J acute brain slices exposed to PTZ, and in wild‐type mice treated with PTZ in vivo. Abnormal locomotion was determined behaviorally in zebrafish and mice and by field potential in neocortex layer IV/V and CA1 stratum pyramidale in the hippocampus.Results: The opioid antagonist naltrexone decreased abnormal locomotion in the larval zebrafish model of human Dravet syndrome (scn1Lab mutants) and wild‐type larvae treated with the pro‐convulsant drug PTZ. Naltrexone also decreased seizure‐like events in acute brain slices of wild‐type mice, and the duration and number of seizures in adult mice injected with PTZ.Significance: Our data reveal that naltrexone has anticonvulsive properties and is a candidate drug for seizure treatment.
- Open Access
- 11 December 2018
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (2) , 295-309
Drug repositioning in epilepsy reveals novel antiseizure candidates
Objective: Epilepsy treatment falls short in ~30% of cases. A better understanding of epilepsy pathophysiology can guide rational drug development in this difficult to treat condition. We tested a low‐cost, drug‐repositioning strategy to identify candidate epilepsy drugs that are already FDA ‐approved and might be immediately tested in epilepsy patients who require new therapies. Methods: Biopsies of spiking and nonspiking hippocampal brain tissue from six patients with unilateral mesial temporal lobe epilepsy were analyzed by RNA ‐Seq. These profiles were correlated with transcriptomes from cell lines treated with FDA ‐approved drugs, identifying compounds which were tested for therapeutic efficacy in a zebrafish seizure assay. Results: In spiking versus nonspiking biopsies, RNA ‐Seq identified 689 differentially expressed genes, 148 of which were previously cited in articles mentioning seizures or epilepsy. Differentially expressed genes were highly enriched for protein–protein interactions and formed three clusters with associated GO ‐terms including myelination, protein ubiquitination, and neuronal migration. Among the 184 compounds, a zebrafish seizure model tested the therapeutic efficacy of doxycycline, metformin, nifedipine, and pyrantel tartrate, with metformin, nifedipine, and pyrantel tartrate all showing efficacy. Interpretation: This proof‐of‐principle analysis suggests our powerful, rapid, cost‐effective approach can likely be applied to other hard‐to‐treat diseases.
- 11 December 2018
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (2) , 295-309
Open AccessDrug repositioning in epilepsy reveals novel antiseizure candidates
Objective: Epilepsy treatment falls short in ~30% of cases. A better understanding of epilepsy pathophysiology can guide rational drug development in this difficult to treat condition. We tested a low‐cost, drug‐repositioning strategy to identify candidate epilepsy drugs that are already FDA ‐approved and might be immediately tested in epilepsy patients who require new therapies. Methods: Biopsies of spiking and nonspiking hippocampal brain tissue from six patients with unilateral mesial temporal lobe epilepsy were analyzed by RNA ‐Seq. These profiles were correlated with transcriptomes from cell lines treated with FDA ‐approved drugs, identifying compounds which were tested for therapeutic efficacy in a zebrafish seizure assay. Results: In spiking versus nonspiking biopsies, RNA ‐Seq identified 689 differentially expressed genes, 148 of which were previously cited in articles mentioning seizures or epilepsy. Differentially expressed genes were highly enriched for protein–protein interactions and formed three clusters with associated GO ‐terms including myelination, protein ubiquitination, and neuronal migration. Among the 184 compounds, a zebrafish seizure model tested the therapeutic efficacy of doxycycline, metformin, nifedipine, and pyrantel tartrate, with metformin, nifedipine, and pyrantel tartrate all showing efficacy. Interpretation: This proof‐of‐principle analysis suggests our powerful, rapid, cost‐effective approach can likely be applied to other hard‐to‐treat diseases.
- 30 December 2016
- Vol. 1 (9) , 23-28
SLC41A1 and TRPM7 in magnesium homeostasis and genetic risk for Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous system with a clinically heterogeneous presentation that includes progressive loss of dopaminergic (DA) neurons in the substantia nigra. A minority of PD cases are familial and are caused by mutations in single genes. Most cases, however, are idiopathic PD, a complex multifactorial disorder with environmental and genetic contributors to etiology. Here, we first briefly summarize published evidence that among environmental contributors is dietary deficiency of magnesium. We then review genetic data suggesting that mutations in genes encoding two proteins contributing to cellular magnesium homeostasis confer risk for PD or other Parkinsonian conditions. First, the gene encoding magnesium transporter SLC41A1 is, among others, a candidate for the causative gene in the PARK16 locus where variation is associated with risk for idiopathic Parkinsonian disease. Studies of the function of SLC41A1 in animal models are needed to test whether this protein has a role in maintenance of dopaminergic neurons. Second, in a small study, a hypomorphic variant of TRPM7, a magnesium-permeable channel, was over-represented in cases of amyotrophic lateral sclerosis/ Parkinson dementia complex versus controls from the same ethnic group. Although this association was not detected in a second study, in zebrafish Trpm7 is necessary for terminal differentiation and reduction of toxin-sensitivity in dopaminergic neurons. Overall, epidemiological results support the possibility that mutations in genes relevant to magnesium homeostasis would alter PD risk, but deeper genetic analyses of PD patients are necessary to confirm whether SLC41A1 and TRPM7 are among such genes.
- 30 December 2016
- Vol. 1 (9) , 23-28
SLC41A1 and TRPM7 in magnesium homeostasis and genetic risk for Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous system with a clinically heterogeneous presentation that includes progressive loss of dopaminergic (DA) neurons in the substantia nigra. A minority of PD cases are familial and are caused by mutations in single genes. Most cases, however, are idiopathic PD, a complex multifactorial disorder with environmental and genetic contributors to etiology. Here, we first briefly summarize published evidence that among environmental contributors is dietary deficiency of magnesium. We then review genetic data suggesting that mutations in genes encoding two proteins contributing to cellular magnesium homeostasis confer risk for PD or other Parkinsonian conditions. First, the gene encoding magnesium transporter SLC41A1 is, among others, a candidate for the causative gene in the PARK16 locus where variation is associated with risk for idiopathic Parkinsonian disease. Studies of the function of SLC41A1 in animal models are needed to test whether this protein has a role in maintenance of dopaminergic neurons. Second, in a small study, a hypomorphic variant of TRPM7, a magnesium-permeable channel, was over-represented in cases of amyotrophic lateral sclerosis/ Parkinson dementia complex versus controls from the same ethnic group. Although this association was not detected in a second study, in zebrafish Trpm7 is necessary for terminal differentiation and reduction of toxin-sensitivity in dopaminergic neurons. Overall, epidemiological results support the possibility that mutations in genes relevant to magnesium homeostasis would alter PD risk, but deeper genetic analyses of PD patients are necessary to confirm whether SLC41A1 and TRPM7 are among such genes.
- Open Access
- 1 January 2016
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 70, 11-21
The Notch ligand E3 ligase, Mind Bomb1, regulates glutamate receptor localization in Drosophila
- 1 January 2016
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 70, 11-21
Open AccessThe Notch ligand E3 ligase, Mind Bomb1, regulates glutamate receptor localization in Drosophila